Effect of sucralfate and basic fibroblast growth factor on fibrovascular ingrowth into hydroxyapatite and porous polyethylene alloplastic implants using a novel rabbit model.
This study investigated the effects of sucralfate and basic fibroblast growth factor (bFGF) on fibrovascular ingrowth into porous implant materials. Seven white female New Zealand rabbits underwent bilateral abdominal incisions through which porous orbital spherical or and disc-shaped implants were inserted between their abdominal muscles. Eighty hydroxyapatite (HA) and porous polyethylene (PP) implants, each material of different pore sizes, were implanted. These implants were either uncoated or coated with suspensions of polyhydroxymethylmethacrylate (hydron); hydron and sucralfate; or hydron, sucralfate, and bFGF. Implants were harvested after 1, 3, or 6 weeks. Observers classified the extent of fibrovascular ingrowth in a blind manner using light microscopy. All discs and spheres showed fibrovascular ingrowth; at 6 weeks, almost all implants were fully vascularized. Although demonstrating different degrees of fibrovascular maturity, all 3- and 6-week discs showed complete cellular ingrowth. Overall, the most extensive and mature fibrovascularization was found in HA implants, regardless of shape, duration of implantation, or angiogenic enhancing agent used. Thus, this study indicates that fibrovascular ingrowth into porous implants is more greatly affected by implant porosity and composition than by addition of angiogenic enhancing agents. Further in vivo study, using other potential angiogenesis-promoting agents as well as implants with different pore characteristics, is warranted using this reliable and predictable animal model.
Rubin
P A
PA
Massachusetts Eye & Ear Infirmary, Boston 02114, USA.
Nicaeus
T E
TE
Warner
M A
MA
Remulla
H D
HD
D000009:Abdominal Muscles / Q000601:surgery; D000818:Animals; D001672:Biocompatible Materials; D002455:Cell Division; D003238:Connective Tissue / Q000098:blood supply* / Q000187:drug effects; D003239:Connective Tissue Cells; D004195:Disease Models, Animal; D017886:Durapatite; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005500:Follow-Up Studies; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D016348:Osseointegration / Q000187:drug effects; D011095:Polyethylenes; D016062:Porosity; D019736:Prostheses and Implants; D011817:Rabbits; D013392:Sucralfate / Q000494:pharmacology*
D001672:Biocompatible Materials; D011095:Polyethylenes; D016222:Fibroblast Growth Factor 2; D013392:Sucralfate; D017886:Durapatite